Spyre Therapeutics, Inc.

NasdaqGS:SYRE Stock Report

Market Cap: US$1.4b

Spyre Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Spyre Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-7.3%

Buyback Yield

Total Shareholder Yield-7.3%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Spyre Therapeutics: Different Name, Same Tune

Dec 12

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Oct 01

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Feb 24
Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Oct 28
We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Aug 18

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aug 04

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Jun 09
Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Dec 07

Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aug 10
Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 08
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SYRE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SYRE's dividend payments have been increasing.


Dividend Yield vs Market

Spyre Therapeutics Dividend Yield vs Market
How does SYRE dividend yield compare to the market?
SegmentDividend Yield
Company (SYRE)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.5%
Industry Average (Biotechs)2.4%
Analyst forecast (SYRE) (up to 3 years)n/a

Notable Dividend: Unable to evaluate SYRE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SYRE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate SYRE's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SYRE has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:13
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Spyre Therapeutics, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Mayur SomaiyaBMO Capital Markets Equity Research
Julian HarrisonBTIG